Torrent Pharmaceuticals Limited has reported strong financial results for the fourth quarter of FY26, marked by a 42% YoY revenue growth to ₹4,197 crore. The company’s consolidated performance was bolstered by the successful integration of JB Pharma, which contributed significantly to consolidated results since January 2026. The Board has also recommended a final dividend of ₹9 per equity share, reflecting confidence in the company’s sustained growth and operational excellence.
Quarterly Financial Performance
For the quarter ended March 31, 2026, Torrent Pharmaceuticals demonstrated robust growth. The company achieved a consolidated revenue of ₹4,197 crore, a significant 42% increase compared to the same period in the previous year. Operating EBITDA for the quarter stood at ₹1,356 crore, representing a 41% year-on-year growth. Excluding the impact of the JB Pharma acquisition, the base business maintained a strong growth trajectory with 16% revenue growth during the quarter.
Strategic Acquisition and Integration
A major highlight for the company in FY26 was the acquisition of a controlling stake in J.B. Chemicals & Pharmaceuticals Limited (JB Pharma). The company successfully completed this acquisition on January 21, 2026. This strategic move is already showing positive momentum, contributing to the consolidated financial results and strengthening the company’s therapeutic presence. Management noted that the integration of JB Pharma is progressing well, with specialized restructuring efforts underway.
Annual Highlights and Dividend Recommendation
For the full financial year FY26, the company recorded consolidated revenues of ₹13,980 crore, up 21% from the previous year. Operating EBITDA for the year reached ₹4,559 crore, showcasing the company’s ability to drive efficiency despite large-scale expansion. Reflecting this strong financial performance, the Board of Directors has recommended a final dividend of ₹9 per equity share, subject to approval by shareholders at the upcoming Annual General Meeting. Additionally, the company received authorization to raise up to ₹5,000 crore through various financial instruments, such as Qualified Institutional Placements (QIP), to support future growth initiatives.
Source: BSE
